# GroundBBreaker 301 (NCT07836530)

> Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07836530
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: BeOne Medicines
- Conditions: Hepatocellular Carcinoma; Liver Cancer
- Interventions: BGB-B2033; Lenvatinib; Sorafenib
- Enrollment: 492
- Primary outcome: Overall Survival (OS)

## Indexed commentary on GroundBBreaker 301 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=groundbbreaker-301-nct07836530
